ROR1 and digestive system neoplasm: Cirmtuzumab (UC-961), a first-in-class humanized anti-ROR1 mAb, had specific antitumor effect on CLL, breast cancer and pancreas ADC cancer without any off-target activity or toxicity in preclinical tests.